Introduction
============

Gastric cancer, one of the most lethal malignancies, is the fourth most common cancer and the second leading deadly cancer in the world.[@b1-cmar-10-765],[@b2-cmar-10-765] According to statistics of the National Central Cancer Registry of China, gastric cancer ranks second in both incidence and mortality of cancers in China.[@b3-cmar-10-765] Despite remarkable progress, the current treatments for gastric cancer are still not efficacious with overall 5-year survival rates \<30%.[@b4-cmar-10-765] One of the main reasons for such a predicament might be that most patients were diagnosed at advanced stages of the disease.[@b5-cmar-10-765] Understanding the underlying mechanisms of gastric cancer initiation and progression may promote biomarker development for early detection of cancer.

Increasing evidence has proven that both environmental and genetic factors contribute to the occurrence and development of gastric cancer.[@b6-cmar-10-765] *Helicobacter pylori* infection is a well-established risk factor for gastric cancer, affecting \>60% of all gastric cancer cases.[@b7-cmar-10-765],[@b8-cmar-10-765] However, not all the *H. pylori*-infected patients finally develop gastric cancer. Many other factors also play roles in gastric carcinogenesis, including micronutrient deficiencies, high body mass index, a high salt or a low fiber diet, over consumption of tobacco or alcohol, as well as genetic risk factors.[@b9-cmar-10-765]--[@b11-cmar-10-765] Increasing numbers of genetic variations have been found to influence susceptibility to gastric cancer in the previous epidemiological studies.[@b12-cmar-10-765],[@b13-cmar-10-765]

The integrity and stability of the genome are primarily maintained by DNA repair systems, which include base excision repair, double strand break repair, mismatch repair, and nucleotide excision repair (NER).[@b14-cmar-10-765],[@b15-cmar-10-765] Among these systems, NER system plays a major role in monitoring and repairing DNA damages caused by exogenous and endogenous factors.[@b16-cmar-10-765] Defects in the NER system might threaten the integrity of genome and thus lead to the development of disease.[@b17-cmar-10-765] It is elucidated that reduced DNA repair capacity is most frequently associated with various human diseases including cancer.[@b18-cmar-10-765] NER process consists of four main steps: damage recognition, damage unwinding, damage incision, and new strand ligation.[@b19-cmar-10-765] There are at least eight key proteins (complementation groups XP-A to G and ERCC1) identified to limit the rate of NER process.[@b20-cmar-10-765] Specifically, XPA and XPC play critical roles in recognizing the DNA damage[@b21-cmar-10-765],[@b22-cmar-10-765]; XPD and XPB are responsible for the process of damage unwinding[@b23-cmar-10-765],[@b24-cmar-10-765]; ERCC1, XPF, and XPG are all essential components for the DNA damage incision.[@b25-cmar-10-765],[@b26-cmar-10-765]

Thus far, several studies have been reported concerning the association between the polymorphisms in the NER pathway genes and the outcomes of gastric cancer.[@b27-cmar-10-765],[@b28-cmar-10-765] However, the association of these polymorphisms with gastric cancer risk was not fully elucidated. Therefore, the aim of this study was to further identify the association between these polymorphisms and gastric cancer susceptibility. In this study, we systematically analyzed the association between nine potential functional single nucleotide polymorphisms (SNPs) in the NER pathway genes (*XPA*, *ERCC1*, *ERCC2*, and *ERCC4*) and gastric cancer risk using 1142 patients and 1173 cancer-free controls in a southern Chinese population.

Materials and methods
=====================

Study population
----------------

This study was approved by the Institutional Review Board of Sun Yat-sen University Cancer Center, Guangzhou, Guangdong. The case group comprised 1142 patients with histologically confirmed gastric cancer enrolled from Sun Yat-sen University Cancer Center from February 2002 to September 2013. The control group consisted of 1173 healthy controls randomly recruited from the same region.[@b29-cmar-10-765],[@b30-cmar-10-765] Enrollment was restricted to unrelated ethnic Han Chinese population from South China. Detailed information was obtained on all subjects, including demographic characteristics (e.g., age and sex), and lifestyle habits (e.g., smoking habits and alcohol drinking). The classification criteria for smoking status and drinking status were described elsewhere.[@b31-cmar-10-765] Written informed consent was acquired from each participant, accompanying with a donation of 5 mL of venous blood sample.

Polymorphism selection and genotyping
-------------------------------------

The potentially functional polymorphisms of main genes in NER pathway were selected from dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP>). Specifically, the following items were set as the selection criteria: 1) located at the 5′ untranslated regions (UTR), upstream promoter region, coding region, and 3′ UTR of genes; 2) the minor allele frequency was \>5% in Chinese Han populations; 3) no obvious linkage between paired SNPs in linkage disequilibrium (R^2^\<0.8). We also adopted SNPinfo (<http://snpinfo.niehs.nih>. gov/snpfunc.htm) to predict the potential functions of those polymorphisms; they could affect the activity of transcription factor binding sites or microRNA binding sites. As a result, the following polymorphisms were included: *XPA* (rs1800975 G\>A, rs3176752 C\>A); *ERCC1* (rs2298881 C\>A, rs11615 G\>A, rs3212986 C\>A); *ERCC2* (rs3810366 C\>G, rs238406 G\>T, rs13181 T\>G); and *ERCC4* rs2276466 C\>G.

DNA was extracted from the blood samples using QIAamp DNA Blood mini kit (QIAGEN Inc, Valencia, CA, USA). Genotyping were performed by the Taqman real-time PCR method on 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, USA), as previously described.[@b31-cmar-10-765]--[@b34-cmar-10-765] For quality control purposes, four duplicate positive controls and four negative controls (without DNA) were used in each of 384-well plates. Moreover, 10% of the samples were randomly selected to re-genotype. There was 100% genotype concordance for each polymorphism among duplicates.

Statistical analysis
--------------------

First, we adopted goodness-of-fit *χ*^2^-test to check whether genotype frequencies of each polymorphism in controls were in Hardy--Weinberg equilibrium (HWE). Then the clinical and demographic characteristics were compared between cases and controls, using the two-sided *χ*^2^-test. To investigate the association of the polymorphisms with gastric cancer risk, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Multivariate analysis using unconditional logistic regression model was performed to calculate adjusted ORs (AORs), with adjustment for age, sex, pack-years, smoking and drinking status. Genotype-based mRNA expressions were also conducted as we described previously.[@b31-cmar-10-765],[@b35-cmar-10-765] All statistical analyses were carried out using version 9.1 SAS software (SAS Institute, Cary, NC, USA). A two-sided *P*-value \<0.05 was used as a criterion of significance.

Results
=======

Population characteristics
--------------------------

This study consisted of 1142 cases of gastric cancer and 1173 healthy controls, whose individual characteristics are shown in [Table S1](#SD1-cmar-10-765){ref-type="supplementary-material"}. With regard to sex, there was no statistically significant difference between cases and controls (65.59% male vs. 67.26% male, *P*=0.393). However, significant differences were observed between cases and controls, regarding age, smoking status, drinking status, and pack-years. Thereafter, these variables were further adjusted for in the subsequent multivariate analyses. Overall, 12.26% (140), 28.81% (329), 39.93% (456), and 19.00% (217) of patients had TNM stage I, II, III, and IV tumors, according to the 7th Edition of the American Joint Committee on Cancer.[@b36-cmar-10-765]

Associations between selected polymorphisms and gastric cancer risk
-------------------------------------------------------------------

The raw data in this paper has been successfully uploaded and locked onto Research Data Deposit with a RDD number of RDDA2018000557. The genotype frequencies of all the selected gene polymorphisms among cases and controls are summarized in [Table 1](#t1-cmar-10-765){ref-type="table"}. All observed genotype frequencies among the controls were conformed to the HWE. In the single locus analysis, we observed a significantly increased gastric cancer risk associated with the *ERCC1* rs2298881 A variant allele (CA vs. CC: AOR=1.33, 95% CI=1.09--1.62; dominant model: AOR=1.32, 95% CI=1.10--1.60; and additive model: AOR=1.20, 95% CI=1.04--1.38). However, *ERCC1* rs3212986 A variant allele contributed to decreased gastric cancer risk (AA vs. CC: AOR=0.73, 95% CI=0.54--0.98; recessive model: AOR=0.72, 95% CI=0.54--0.96). There were no significant associations between the rest of all SNPs and gastric cancer risk.

Stratification analysis
-----------------------

Stratified analysis was performed to further analyze the association of two independent *ERCC1* rs2298881 C\>A, rs3212986 C\>A polymorphisms and gastric cancer risk by age, sex, smoking status, pack-years, drinking status, tumor sites, and TNM stage ([Table 2](#t2-cmar-10-765){ref-type="table"}). The risk association with the *ERCC1* rs2298881 CA/AA genotypes remained significant in the following subgroups: males (AOR=1.37, 95% CI=1.08--1.73), never-smokers (AOR=1.40, 95% CI=1.09--1.79), 0 pack-year (AOR=1.40, 95% CI=1.09--1.79), ≤30 pack-years (AOR=1.74, 95% CI=1.19--2.54), never drinkers (AOR=1.36, 95% CI=1.09--1.69), non-cardia (AOR=1.31, 95% CI=1.08--1.60), stage I/II (AOR=1.42, 95% CI=1.11--1.82), and stage III/IV (AOR=1.28, 95% CI=1.03--1.59). Moreover, the *ERCC1* rs3212986 C\>A polymorphism AA variant significantly reduced gastric cancer risk in the following subgroups: age ≤58 years (AOR=0.66, 95% CI=0.47--0.93), males (AOR=0.65, 95% CI=0.46--0.92), never drinkers (AOR=0.70, 95% CI=0.50--0.98), and noncardia (AOR=0.72, 95% CI=0.53--0.97).

We also performed a stratification analysis for the *ERCC2* gene rs3810366 C\>G and rs238406 G\>T polymorphisms ([Table 3](#t3-cmar-10-765){ref-type="table"}). Both the rs3810366 (AOR=1.32, 95% CI=1.04--1.68) and rs238406 (AOR=1.32, 95% CI=1.03--1.69) polymorphisms conferred gastric cancer susceptibility in never drinkers.

Correlation analysis for ERCC1 mRNA expression levels and genotypes
-------------------------------------------------------------------

We further conducted the *ERCC1* genotype expression correlation analysis ([Table S2](#SD2-cmar-10-765){ref-type="supplementary-material"}), aiming to explore underlying molecular mechanisms. The genotype data for 270 individuals were collected from HapMap. *ERCC1* mRNA expression levels of lymphoblastoid cell lines from the same 270 individuals were extracted from SNPexp. We observed that genotypes of the rs2298881 C\>A polymorphism were significantly correlated with decreased *ERCC1* mRNA expression in Chinese subjects (*P*=0.003), Africans (*P*\<0.0001), and combined subjects (*P*\<0.0001). However, no genotype expression correlation was found for the rs3212986 C\>A and rs11615 G\>A polymorphisms in combined subjects.

Discussion
==========

In the present hospital-based case-control study, we investigated the association between the polymorphisms in the NER genes and gastric cancer risk in a southern Chinese population. We observed a significantly increased gastric cancer risk associated with the *ERCC1* rs2298881 A variant allele. However, we found that *ERCC1* rs3212986 A variant allele was associated with decreased risk of gastric cancer. We also confirmed that the *ERCC1* rs2298881 C\>A polymorphism was associated with a decrease in *ERCC1* mRNA expression. However, no association with gastric cancer risk was detected for the polymorphisms in the *XPA*, *XPD*, and *XPF* genes. To the best of our knowledge, this is by far the most comprehensive study investigating the association between the NER pathway genes and gastric cancer risk.

*ERCC1* gene is located on chromosome 19q32.32, consisting of 10 exons and encoding a 297 amino acid protein. The ERCC1 protein is an indispensable component of the NER pathway.[@b37-cmar-10-765],[@b38-cmar-10-765] It interacts with XPA, XPF, and/or RPA, and catalyzes the 5′ cleavage of DNA lesions.[@b39-cmar-10-765] Given the critical role of ERCC1 protein in NER, it is biologically plausible that potentially functional *ERCC1* gene variants could modify gastric cancer risk. Our findings are in accordance with others. For instance, He et al reported that *ERCC1* rs11615 G\>A was associated with an increased risk of breast cancer.[@b40-cmar-10-765] Likewise, the *ERCC1* rs11615 G\>A polymorphism was shown to increase the risk of developing lung cancer.[@b41-cmar-10-765] It is worth mentioning that we previously observed that *ERCC1* rs11615A and rs2298881C variant alleles were associated with increased gastric cancer risk in an eastern Chinese population.[@b42-cmar-10-765] Moreover, patients with 2--3 *ERCC1* risk genotypes had a significantly increased risk of gastric cancer compared with those with 0--1 *ERCC1* risk genotypes.[@b42-cmar-10-765] However, the previous study did not detect an association between the rs3212986 polymorphism and gastric cancer risk. The discrepant results between the former study and the present study might be due to the different population selected. Our previous study population was recruited from East China, while the current study population was recruited from South China. Apart from our studies, two published studies regarding *ERCC1* polymorphisms and gastric cancer risk were conducted in Italian population with relatively small sample sizes.[@b43-cmar-10-765],[@b44-cmar-10-765] One study included 314 cases and 548 controls, and the other included 126 cases and 144 controls. No significant association was detected in these two studies. However, all the included polymorphisms of *ERCC1* in these two studies were not under investigation in the present study.

In the stratification analysis, our data suggested that the risk effect of *ERCC1* rs2298881 CA/AA genotypes remained significant in males, never-smokers, pack-year of 0, pack-years ≤30, never drinkers, non-cardia, stage I/II, and stage III/IV subgroups. The association between decreased gastric cancer risk and *ERCC1* rs3212986 was more evident in subgroups of median age ≤58 years, males, never-drinkers, and non-cardia tumor. This phenomenon can be explained by the concept that susceptible individuals are likely to have a light exposure to risk factors. Young individuals, never smokers, or never drinkers are tended to be exposed to less environmental carcinogens. Thus, the role of genetic variants might not be outweighed by carcinogens in carcinogenesis in such subgroups. Considering the reduced sample sizes in the stratification analysis, some results might be just chance findings. Therefore, these results should be interpreted with caution. We further adopted the public data on *ERCC1* genotypes and mRNA levels for the genotype--phenotype association analysis. A significant correlation between *ERCC1* mRNA levels and rs2298881 C\>A genotypes was observed, which provide further evidence that rs2298881 C\>A may associate with gastric cancer by mRNA expression alteration, sequentially DNA repair capacity alteration. Therefore, additional larger case-control studies with functional analysis are warranted to explore the exact role of *ERCC1* in gastric cancer risk.

We failed to detect any relationship between other polymorphisms and gastric cancer risk. Lack of an association of gastric cancer susceptibility with single NER pathway gene variants was also reported by other studies. For instance, in a case-control study including 246 cases and 1175 controls, no significant association was observed between the analyzed polymorphisms in the *MSH2*, *MLH1*, *XRCC1*, *OGG1*, and *ERCC2* genes and gastric cancer risk.[@b45-cmar-10-765] However, some previous studies have demonstrated that some polymorphisms including rs11615 G\>A were independent risk factors for gastric cancer.[@b42-cmar-10-765] Such a discrepancy among studies might be partly due to the limited sample sizes; small sample studies may not have sufficient statistical power to reveal an association. Another possible explanation was that the effect of each single variant was too weak to be detected. Moreover, the potential effect of polymorphisms in gastric cancer risk may be dissimulated by other complex exposures or environmental--genetic interactions.

Although we extensively analyzed a number of polymorphisms in the NER core pathway genes, some limitations still existed in this study. First, due to the nature of a retrospective study, selection bias and recall bias could not be completely avoided. To minimize such biases, we further performed multivariate logistic regression analysis on potential confounding factors such as age, smoking, and drinking status. Second, gastric cancer is a heterogeneous disease affected by multiple factors including *H. pylori* infection, environmental exposures, and diet habits, yet these data were not available for further analysis. Third, the sample size in the subgroup analysis was relatively small, which might limit the statistical power in the stratification analysis. Fourth, we adopted only the public data to preliminarily investigate the correlation between *ERCC1* genotype and mRNA expression. The findings should be validated in gastric tissues in the future. We failed to quantify the *ERCC1* mRNA levels in the target tissue of the included subjects due to tissue access constraints. Finally, as all participants were recruited from a hospital in South China, special caution should be paid in extrapolating the results to other populations.

In conclusion, we found that the *ERCC1* gene rs2298881 C\>A and rs3212986 C\>A polymorphisms were associated with gastric cancer susceptibility in a southern Chinese population. Well-designed studies with larger sample sizes and functional analysis are required to further verify our findings.

Supplementary materials
=======================

###### 

Clinical and demographic characteristics of gastric cancer cases and cancer-free controls

  Variables         No. of cases (%)   No. of controls (%)   *P*-value[a](#tfn8-cmar-10-765){ref-type="table-fn"}
  ----------------- ------------------ --------------------- ------------------------------------------------------
  All subjects      1142 (100.0)       1173 (100.0)          
  Gender                                                     
   Male             749 (65.6)         789 (67.3)            0.393
   Female           393 (34.4)         384 (32.7)            
  Age, years        15--86             16--80                
  Mean±SD           56.3±12.5          45.2±11.6             \<0.0001
   ≤50              334 (29.3)         789 (67.3)            
   51--60           362 (31.7)         285 (24.3)            
   61--70           312 (27.3)         73 (6.2)              
   \>70             134 (11.7)         26 (2.2)              
  Smoking status                                             
   Never            735 (64.4)         662 (56.4)            \<0.0001
   Ever             407 (35.6)         511 (43.6)            
  Drinking status                                            
   No               934 (81.8)         600 (51.2)            \<0.0001
   Yes              208 (18.2)         573 (48.8)            
  Pack-years                                                 
   0                735 (64.4)         662 (56.4)            \<0.0001
   ≤30              272 (23.8)         383 (32.7)            
   \>30             135 (11.8)         128 (10.9)            
  Sites                                                      
   Cardia           240 (21.0)         --                    
   Non-cardia       902 (79.0)         --                    
  TNM stages                                                 
   I                140 (12.3)         --                    
   II               329 (28.8)         --                    
   III              456 (39.9)         --                    
   IV               217 (19.0)         --                    

**Note:**

Two-sided chi-square test for distributions between gastric cancer cases and cancer-free controls.

###### 

*ERCC1* mRNA expression by the genotypes of polymorphisms, using data from the HapMap[a](#tfn9-cmar-10-765){ref-type="table-fn"}

  Population   mRNA expression (rs2298881)   mRNA expression (rs3212986)   mRNA expression (rs11615)                                                                                                                                                                      
  ------------ ----------------------------- ----------------------------- --------------------------- ---------------------------------------------------------- ------- ----- ----------- --------------------------------------------------- ------- ----- ----------- -------------------------------------------------------
  CHB          CC                            15                            6.81±0.08                   **0.003**[c](#tfn11-cmar-10-765){ref-type="table-fn"}      CC      20    6.74±0.13   0.442[c](#tfn11-cmar-10-765){ref-type="table-fn"}   GG      29    6.73±0.11   **0.044**[c](#tfn11-cmar-10-765){ref-type="table-fn"}
               AC                            20                            6.76±0.09                   0.126                                                      AC      19    6.77±0.09   0.416                                               AG      12    6.79±0.10   0.144
               AA                            10                            6.68±0.13                   **0.006**                                                  AA      5     6.77±0.07   0.664                                               AA      4     6.83±0.07   0.111
               AC/AA                         30                            6.73±0.11                   **0.026**                                                  AC/AA   24    6.77±0.08   0.377[d](#tfn12-cmar-10-765){ref-type="table-fn"}   AG/AA   16    6.80±0.09   0.054
  JPT          CC                            9                             6.81±0.07                   0.242[c](#tfn11-cmar-10-765){ref-type="table-fn"}          CC      31    6.75±0.09   0.442[c](#tfn11-cmar-10-765){ref-type="table-fn"}   GG      21    6.75±0.10   0.872[c](#tfn11-cmar-10-765){ref-type="table-fn"}
               AC                            26                            6.74±0.11                   0.067                                                      AC      13    6.77±0.12   0.442                                               AG      22    6.76±0.10   0.846
               AA                            10                            6.76±0.08                   0.118                                                      AA      0     --          --                                                  AA      2     6.76±0.06   0.976
               AC/AA                         36                            6.74±0.10                   0.060                                                      AC/AA   13    6.77±0.12   0.442[d](#tfn12-cmar-10-765){ref-type="table-fn"}   AG/AA   24    6.76±0.10   0.848
  CEU          CC                            79                            6.77±0.12                   0.370[c](#tfn11-cmar-10-765){ref-type="table-fn"}          CC      52    6.77±0.13   0.725[c](#tfn11-cmar-10-765){ref-type="table-fn"}   GG      6     6.85±0.13   0.447[c](#tfn11-cmar-10-765){ref-type="table-fn"}
               AC                            11                            6.74±0.18                   0.370                                                      AC      35    6.74±0.12   0.279                                               AG      49    6.76±0.14   0.168
               AA                            0                             --                          --                                                         AA      3     6.95±0.04   **0.026**                                           AA      35    6.77±0.11   0.111
               AC/AA                         11                            6.74±0.18                   0.370                                                      AC/AA   38    6.76±0.13   0.620                                               AG/AA   84    6.76±0.13   0.129
  YRI          CC                            76                            6.80±0.09                   \<**0.0001**[c](#tfn11-cmar-10-765){ref-type="table-fn"}   CC      39    6.77±0.10   0.208[c](#tfn11-cmar-10-765){ref-type="table-fn"}   GG      87    6.79±0.10   0.137[c](#tfn11-cmar-10-765){ref-type="table-fn"}
               AC                            11                            6.71±0.07                   **0.002**                                                  AC      45    6.81±0.09   **0.046**                                           AG      3     6.71±0.05   0.137
               AA                            2                             6.61±0.003                  **0.004**                                                  AA      6     6.76±0.05   0.976                                               AA      0     --          --
               AC/AA                         13                            6.70±0.07                   **0.0001**[d](#tfn12-cmar-10-765){ref-type="table-fn"}     AC/AA   51    6.80±0.09   0.065                                               AG/AA   3     6.71±0.05   0.137
  All          CC                            179                           6.79±0.10                   \<**0.0001**[c](#tfn11-cmar-10-765){ref-type="table-fn"}   CC      142   6.76±0.11   0.095[c](#tfn11-cmar-10-765){ref-type="table-fn"}   GG      143   6.78±0.10   0.599[c](#tfn11-cmar-10-765){ref-type="table-fn"}
               AC                            68                            6.74±0.11                   **0.001**                                                  AC      112   6.78±0.11   0.243                                               AG      86    6.76±0.12   0.385
               AA                            22                            6.71±0.11                   **0.001**                                                  AA      14    6.80±0.09   0.162                                               AA      41    6.77±0.10   0.793
               AC/AA                         90                            6.73±0.11                   \<**0.0001**[d](#tfn12-cmar-10-765){ref-type="table-fn"}   AC/AA   126   6.78±0.10   0.149[d](#tfn12-cmar-10-765){ref-type="table-fn"}   AG/AA   127   6.77±0.12   0.435

**Notes:**

*ERCC1* genotyping data and mRNA expression levels for *ERCC1* by genotypes were obtained from the HapMap Phase II release 23 data from EBV-transformed lymphoblastoid cell lines from 270 individuals, including 45 unrelated CHB.

Two-sided Student's *t*-test within the stratum.

*P*-values for the trend test of *ERCC1* mRNA expression among three genotypes for each polymorphism from a general linear model.

There were missing data because genotyping data were not available. Bold represents any values *P*\<0.05.

**Abbreviations:** CEU, Utah residents with ancestry from northern and western Europe; CHB, Han Chinese in Beijing, China; JPT, Japanese in Tokyo; YRI, Yoruba in Ibadan, Nigeria.

This study was supported by grants from National Natural Science Foundation of China (Grant No. 81502046), the Natural Science Foundation of Guangdong Province (Grant No. 2015A030310324), and the National Science Fund for Distinguished Young Scholars (Grant No. 81325018).
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###### 

Associations between selected polymorphisms and gastric cancer risk

  Genotypes                 Cases (N=1141)   Controls (N=1173)   *P*-value[a](#tfn1-cmar-10-765){ref-type="table-fn"}   OR (95% CI)                 *P*-value   AOR (95% CI)                *P*-value[b](#tfn2-cmar-10-765){ref-type="table-fn"}
  ------------------------- ---------------- ------------------- ------------------------------------------------------ --------------------------- ----------- --------------------------- ------------------------------------------------------
  *XPA* rs1800975 G\>A                                                                                                                                                                      
   GG                       296 (25.94)      327 (27.88)                                                                1.00                                    1.00                        
   GA                       575 (50.39)      590 (50.30)                                                                1.08 (0.89--1.31)           0.458       1.01 (0.81--1.26)           0.954
   AA                       270 (23.66)      256 (21.82)                                                                1.17 (0.92--1.47)           0.197       1.05 (0.81--1.37)           0.693
   Dominant                 845 (74.06)      846 (72.12)         0.294                                                  1.10 (0.92--1.33)           0.295       1.02 (0.83--1.26)           0.843
   Additive model                                                0.435                                                  1.08 (0.96--1.21)           0.197       1.03 (0.90--1.17)           0.702
   Recessive                871 (76.34)      917 (78.18)         0.291                                                  1.11 (0.91--1.35)           0.291       1.05 (0.84--1.31)           0.665
  *XPA* rs3176752 C\>A                                                                                                                                                                      
   CC                       801 (70.20)      824 (70.25)                                                                1.00                                    1.00                        
   CA                       316 (27.70)      318 (27.11)                                                                1.02 (0.85--1.23)           0.814       1.03 (0.84--1.27)           0.760
   AA                       24 (2.10)        31 (2.64)                                                                  0.80 (0.46--1.37)           0.410       0.92 (0.50--1.71)           0.794
   Dominant                 340 (29.80)      349 (29.75)         0.981                                                  1.00 (0.84--1.20)           0.981       1.02 (0.84--1.25)           0.821
   Additive model                                                0.677                                                  0.98 (0.84--1.15)           0.818       1.01 (0.84--1.21)           0.908
   Recessive                1117 (97.90)     1142 (97.36)        0.394                                                  0.79 (0.46--1.36)           0.395       0.91 (0.50--1.69)           0.771
  *ERCC1* rs2298881 C\> A                                                                                                                                                                   
   CC                       461 (40.40)      540 (46.04)                                                                1.00                                    1.00                        
   CA                       548 (48.03)      500 (42.63)                                                                **1.28 (1.08**--**1.53)**   **0.005**   **1.33 (1.09**--**1.62)**   **0.005**
   AA                       132 (11.57)      133 (11.34)                                                                1.16 (0.89--1.52)           0.276       1.31 (0.96--1.78)           0.087
   Dominant                 680 (59.60)      633 (53.96)         **0.006**                                              **1.26 (1.07**--**1.48)**   **0.006**   **1.32 (1.10**--**1.60)**   **0.003**
   Additive model                                                **0.018**                                              **1.14 (1.01**--**1.29)**   **0.035**   **1.20 (1.04**--**1.38)**   **0.010**
   Recessive                1009 (88.43)     1940 (88.66)        0.862                                                  1.02 (0.79--1.32)           0.862       1.13 (0.85--1.51)           0.404
  *ERCC1* rs11615 G\>A                                                                                                                                                                      
   GG                       594 (52.06)      592 (50.47)                                                                1.00                                    1.00                        
   GA                       465 (40.75)      489 (41.69)                                                                0.95 (0.80--1.12)           0.537       0.94 (0.78--1.14)           0.533
   AA                       82 (7.19)        92 (7.84)                                                                  0.89 (0.65--1.22)           0.467       0.86 (0.60--1.22)           0.392
   Dominant                 547 (47.94)      581 (49.53)         0.444                                                  0.94 (0.80--1.11)           0.444       0.93 (0.77--1.12)           0.418
   Additive model                                                0.691                                                  0.95 (0.83--1.08)           0.391       0.93 (0.81--1.08)           0.344
   Recessive                1059 (92.81)     1081 (92.16)        0.549                                                  0.91 (0.67--1.24)           0.550       0.88 (0.62--1.24)           0.468
  *ERCC1* rs3212986 C\> A                                                                                                                                                                   
   CC                       477 (41.81)      478 (40.75)                                                                1.00                                    1.00                        
   CA                       535 (46.89)      535 (45.61)                                                                1.00 (0.84--1.19)           0.981       1.02 (0.83--1.24)           0.878
   AA                       129 (11.31)      160 (13.64)                                                                0.81 (0.62--1.05)           0.114       **0.73 (0.54**--**0.98)**   **0.037**
   Dominant                 664 (58.19)      695 (59.25)         0.606                                                  0.96 (0.81--1.13)           0.606       0.95 (0.78--1.14)           0.565
   Additive model                                                0.236                                                  0.93 (0.82--1.05)           0.227       0.90 (0.78--1.03)           0.125
   Recessive                1012 (88.69)     1013 (86.36)        0.090                                                  0.81 (0.63--1.03)           0.090       **0.72 (0.54**--**0.96)**   **0.023**
  ERCC2 rs3810366 C\>G                                                                                                                                                                      
   CC                       331 (29.01)      379 (32.31)                                                                1.00                                    **1.00**                    
   CG                       560 (49.08)      554 (47.23)                                                                1.16 (0.96--1.40)           0.129       **1.21 (0.98--1.50)**       **0.079**
   GG                       250 (21.91)      240 (20.46)                                                                1.19 (0.95--1.50)           0.134       **1.20 (0.92--1.55)**       **0.181**
   Dominant                 810 (70.99)      794 (67.69)         0.085                                                  1.17 (0.98--1.39)           0.086       **1.21 (0.99--1.48)**       **0.067**
   Additive model                                                0.219                                                  1.10 (0.98--1.23)           0.110       **1.10 (0.97--1.26)**       **0.138**
   Recessive                891 (78.09)      933 (79.54)         0.393                                                  1.09 (0.89--1.33)           0.393       **1.06 (0.85--1.33)**       **0.598**
  ERCC2 rs238406 G\>T                                                                                                                                                                       
   GG                       296 (25.94)      343 (29.24)                                                                1.00                                    **1.00**                    
   GT                       556 (48.73)      564 (48.08)                                                                1.14 (0.94--1.39)           0.181       **1.20 (0.96--1.49)**       **0.112**
   TT                       289 (25.33)      266 (22.68)                                                                1.26 (1.00--1.58)           0.048       **1.26 (0.97--1.63)**       **0.081**
   Dominant                 845 (74.06)      830 (70.76)         0.076                                                  1.18 (0.98--1.42)           0.077       **1.22 (0.99--1.50)**       **0.063**
   Additive model                                                0.134                                                  1.12 (1.00--1.26)           0.046       **1.12 (0.99--1.28)**       **0.075**
   Recessive                852 (74.67)      907 (77.32)         0.135                                                  1.16 (0.96--1.40)           0.136       **1.12 (0.90--1.39)**       **0.295**
  ERCC2 rs13181 T\>G                                                                                                                                                                        
   TT                       971 (85.10)      982 (83.72)                                                                1.00                                    **1.00**                    
   TG                       161 (14.11)      187 (15.94)                                                                0.87 (0.69--1.09)           0.235       **0.85 (0.66--1.10)**       **0.220**
   GG                       9 (0.79)         4 (0.34)                                                                   2.28 (0.70--7.41)           0.173       **1.37 (0.38--4.99)**       **0.636**
   Dominant                 170 (14.90)      191 (16.28)         0.359                                                  0.90 (0.72--1.13)           0.360       **0.87 (0.67--1.12)**       **0.262**
   Additive model                                                0.175                                                  0.94 (0.76--1.16)           0.557       **0.89 (0.70--1.13)**       **0.335**
   Recessive                1132 (99.21)     1169 (99.66)        0.150                                                  2.32 (0.71--7.56)           0.162       **1.40 (0.38--5.11)**       **0.609**
  ERCC4 rs2276466 C\>G                                                                                                                                                                      
   CC                       663 (58.11)      726 (61.89)                                                                1.00                                    **1.00**                    
   CG                       418 (36.63)      383 (32.65)                                                                1.20 (1.004--1.42)          0.045       **1.12 (0.92--1.36)**       **0.272**
   GG                       60 (5.26)        64 (5.46)                                                                  1.03 (0.71--1.48)           0.889       **0.96 (0.64--1.46)**       **0.860**
   Dominant                 478 (41.89)      447 (38.11)         0.063                                                  1.17 (0.99--1.38)           0.063       **1.10 (0.91--1.32)**       **0.348**
   Additive model                                                0.130                                                  1.11 (0.97--1.27)           0.148       **1.05 (0.90--1.23)**       **0.530**
   Recessive                1081 (94.74)     1109 (94.54)        0.833                                                  0.96 (0.67--1.38)           0.833       **0.93 (0.62--1.39)**       **0.709**

**Notes:**

Chi-square test for genotype distributions between cases and controls.

Adjusted for age, gender, smoking, and drinking status. Bold represents any values with a 95% CI excluding 1 or *P*\<0.05.

**Abbreviations:** AOR, adjusted odds ratio; OR, odds ratio.

###### 

Stratification analysis of *ERCC1* gene variant genotypes with gastric cancer risk

  Variables           rs2298881 (cases/controls)   AOR (95% CI)   *P*-value[a](#tfn4-cmar-10-765){ref-type="table-fn"}   rs3212986 (cases/controls)   AOR (95% CI)   *P*-value[a](#tfn4-cmar-10-765){ref-type="table-fn"}                               
  ------------------- ---------------------------- -------------- ------------------------------------------------------ ---------------------------- -------------- ------------------------------------------------------ --------------------------- -----------
  Median age, years                                                                                                                                                                                                                                     
   ≤58                250/470                      348/546        1.23 (0.99--1.52)                                      0.062                        540/877        58/139                                                 **0.66 (0.47**--**0.93)**   **0.017**
   \>58               211/70                       332/87         1.29 (0.89--1.85)                                      0.176                        472/136        71/21                                                  0.97 (0.57--1.65)           0.914
  Gender                                                                                                                                                                                                                                                
   Male               310/371                      439/418        **1.37 (1.08**--**1.73)**                              **0.009**                    663/677        86/112                                                 **0.65 (0.46**--**0.92)**   **0.016**
   Female             151/169                      241/215        1.26 (0.92--1.72)                                      0.159                        349/336        43/48                                                  0.90 (0.55--1.47)           0.679
  Smoking status                                                                                                                                                                                                                                        
   Never              298/305                      436/357        **1.40 (1.09**--**1.79)**                              **0.008**                    644/571        90/91                                                  0.76 (0.53--1.10)           0.143
   Ever               163/235                      244/276        1.26 (0.93--1.70)                                      0.134                        368/442        39/69                                                  0.68 (0.42--1.08)           0.102
  Pack-years                                                                                                                                                                                                                                            
   0                  298/305                      436/357        **1.40 (1.09**--**1.79)**                              **0.008**                    644/571        90/91                                                  0.76 (0.53--1.10)           0.143
   ≤30                102/182                      170/201        **1.74 (1.19**--**2.54)**                              **0.004**                    248/331        24/52                                                  0.56 (0.31--1.01)           0.053
   \>30               61/53                        74/75          0.71 (0.42--1.21)                                      0.205                        120/111        15/17                                                  0.92 (0.41--2.04)           0.833
  Drinking status                                                                                                                                                                                                                                       
   Never              377/282                      556/318        **1.36 (1.09**--**1.69)**                              **0.007**                    827/516        106/84                                                 **0.70 (0.50**--**0.98)**   **0.035**
   Ever               84/258                       124/315        1.28 (0.88--1.86)                                      0.201                        185/497        23/76                                                  0.79 (0.45--1.41)           0.429
  Tumor site                                                                                                                                                                                                                                            
   Cardia             102/540                      138/633        1.36 (0.99--1.87)                                      0.059                        212/1013       28/160                                                 0.76 (0.47--1.22)           0.252
   Non-cardia         359/540                      542/633        **1.31 (1.08**--**1.60)**                              **0.007**                    800/1013       101/160                                                **0.72 (0.53**--**0.97)**   **0.030**
  TNM stage                                                                                                                                                                                                                                             
   I/II               184/540                      285/633        **1.42 (1.11**--**1.82)**                              **0.006**                    414/1013       55/160                                                 0.74 (0.51--1.07)           0.112
   III/IV             277/540                      395/633        **1.28 (1.03**--**1.59)**                              **0.024**                    598/1013       74/160                                                 0.72 (0.52--1.00)           0.050

**Notes:**

Obtained in logistic regression models with adjustment for age, sex, pack-years, smoking, and drinking status, omitting the corresponding stratification factor. Bold represents any values with a 95% CI excluding 1 or *P*\<0.05.

**Abbreviation:** AOR, adjusted odds ratio.

###### 

Stratification analysis of *ERCC2* gene variant genotypes with gastric cancer risk

  Variables           rs3810366 (cases/controls)   AOR (95% CI)   *P*-value[a](#tfn6-cmar-10-765){ref-type="table-fn"}   rs238406 (cases/controls)   AOR (95% CI)   *P*-value[a](#tfn6-cmar-10-765){ref-type="table-fn"}                               
  ------------------- ---------------------------- -------------- ------------------------------------------------------ --------------------------- -------------- ------------------------------------------------------ --------------------------- -----------
  Median age, years                                                                                                                                                                                                                                    
   ≤58                173/331                      425/685        1.19 (0.94--1.50)                                      0.145                       157/298        441/718                                                1.17 (0.92--1.48)           0.196
   \>58               158/48                       385/109        1.06 (0.72--1.57)                                      0.755                       139/45         404/112                                                1.17 (0.79--1.75)           0.437
  Gender                                                                                                                                                                                                                                               
   Males              227/266                      522/523        1.20 (0.93--1.54)                                      0.155                       201/242        548/547                                                1.22 (0.95--1.58)           0127
   Females            104/113                      288/271        1.25 (0.88--1.76)                                      0.215                       95/101         297/283                                                1.24 (0.87--1.77)           0.234
  Smoking status                                                                                                                                                                                                                                       
   Never              211/202                      523/460        1.19 (0.91--1.55)                                      0.207                       194/182        540/480                                                1.20 (0.91--1.58)           0.188
   Ever               120/177                      287/334        1.27 (0.92--1.75)                                      0.142                       102/161        305/350                                                1.32 (0.95--1.83)           0.103
  Pack-years                                                                                                                                                                                                                                           
   0                  211/202                      523/460        1.19 (0.91--1.55)                                      0.207                       194/182        540/480                                                1.20 (0.91--1.58)           0.188
   ≤30                80/137                       192/246        1.43 (0.97--2.12)                                      0.075                       70/126         202/257                                                1.44 (0.96--2.16)           0.075
   \>30               40/40                        95/88          1.07 (0.61--1.87)                                      0.824                       32/35          103/93                                                 1.19 (0.66--2.16)           0.564
  Drinking status                                                                                                                                                                                                                                      
   Never              264/199                      669/401        **1.32 (1.04**--**1.68)**                              **0.022**                   238/181        695/419                                                **1.32 (1.03**--**1.69)**   **0.027**
   Ever               67/180                       141/393        1.03 (0.69--1.53)                                      0.888                       58/162         150/411                                                1.13 (0.74--1.69)           0.602
  Tumor site                                                                                                                                                                                                                                           
   Cardia             75/379                       165/794        1.19 (0.85--1.67)                                      0.318                       67/343         173/830                                                1.20 (0.84--1.70)           0.318
   Non-cardia         256/379                      645/794        1.19 (0.97--1.48)                                      0.103                       229/343        672/830                                                1.21 (0.97--1.50)           0.093
  TNM stage                                                                                                                                                                                                                                            
   I/II               143/379                      326/794        1.18 (0.91--1.53)                                      0.223                       126/343        343/830                                                1.22 (0.93--1.60)           0.152
   III/IV             188/379                      484/794        1.22 (0.97--1.54)                                      0.088                       170/343        502/830                                                1.21 (0.95--1.54)           0.116

**Notes:**

Obtained in logistic regression models with adjustment for age, gender, pack-years, smoking, and drinking status, omitting the corresponding stratification factor. Bold represents any values with a 95% CI excluding 1 or *P*\<0.05.

**Abbreviation:** AOR, adjusted odds ratio.
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